Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Daewoo Pharmaceutical Co., Ltd.
WARNING LETTER
•Daewoo Pharmaceutical Co., Ltd.•January 15, 2025

Daewoo Pharmaceutical Co., Ltd. – FDA Warning Letter, Jan 15, 2025

Record Details

Daewoo Pharmaceuticals Co., Ltd., located in Busan, South Korea, was inspected by the FDA from January 6 to 15, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, as outlined in Title 21 CFR parts 210 and 211. These violations render the drug products adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.

Key issues identified include:

1. **Inadequate Aseptic Processing**: The firm failed to establish and follow procedures to prevent microbiological contamination in sterile drug products. Smoke studies revealed turbulent airflow in critical areas, and media fills did not accurately simulate commercial operations, lacking representation of routine production interventions.

2. **Poor Aseptic Practices**: Observations included insufficient personnel monitoring and inadequate training for operators in ISO 5 areas, which compromised sterility assurance.

3. **Contamination Risks**: The design of the aseptic processing line was inadequate, with gaps affecting airflow and improper sterilization of equipment. Environmental monitoring lacked scientific justification, posing a contamination risk.

4. **Insufficient Production Controls**: The visual inspection process was inadequate, lacking proper defect identification and quality assurance measures.

The FDA requires Daewoo Pharmaceuticals to address these deficiencies by providing detailed corrective actions, including plans for redesigning the aseptic processing line, enhancing personnel training, and improving environmental and visual inspection protocols. Failure to adequately address these issues may result in regulatory actions, impacting the firm"s ability to market products in the U.S.

Company
Daewoo Pharmaceutical Co., Ltd.
Inspection date
January 15, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Sarah E. Rhoades (Investigator)
View Company Profile

ID · b2da3b8e-d146-4e6e-9151-ac586707c077

Violation Codes10
21 CFR 21121 CFR 211.100(a)21 CFR 211.198(a)FD&C Act 801(a)(3)21 CFR 211.113(b)21 CFR 211.2221 CFR 211.67(b)21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211.42(c)(10)

Full citation text and observation details available on the Dashboard.

Other documents for Daewoo Pharmaceutical Co., Ltd.
  • 483 - 2025-01-15January 15, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Daewoo Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.